Vaccines Market Research Reports & Industry Analysis

Vaccine stands for a preparation of dead, attenuate or else modified viruses, bacteria and other microorganisms utilized as an inoculation to immunize against any disease by way of stimulating antibodies’ production. With constant technology upgrades and launches of new medicinal products, Vaccines proved to be the most sophisticated healthcare aid ever created in the pharma’s history.

The global Vaccine Industry is thriving mainly owing to the chronic availability of different diseases, both already-existing and cropping up on the horizon, which can be luckily prevented with Vaccines’ assistance. Pediatric Vaccines form the largest and the most hastily evolving segment as against adult Vaccines, with the trend predicted to stay unaltered in the impending period. The worldwide Vaccine Market is primarily in the paws of such behemoths as Merck & Company, Inc.; Novartis, Pfizer, Inc.; GlaxoSmithKline plc; and Sanofi Pasteur.

The research reports under this Catalogue provide in-depth assessments of the global Vaccine Industry, discussing pressing market issues and statistical figures. The research reports cover the sizing (value/volume) and short-to-long-run forecasts for the overall Vaccine Market and its major segments, and for numerous geographic markets. The listing of M&As among the Vaccine universe participants with new products’ reviews, alongside company profile information can be derived from the research reports too.

Found 402 publications
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players US$ 2,995.00

Summary GlobalData has released its pharma report, “PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players”. The report is a vital ... with in-depth analysis on the companies in the rapidly growing Prophylactic hepatitis B virus vaccines Market. The report identifies and analyses the ...

Jan, 2014 70 pages
Vaccine Development Strategies - Refocusing Efforts to Address New Challenges US$ 3,900.00

... , including recent activities of major pharmaceutical companies, insight into the challenges being faced by companies developing therapeutic vaccines and recommendations on clinical development strategies to overcome these potential obstacles and hurdles The report assesses the evolving competitive vaccines ...

Feb, 2014 60 pages
Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people ...

Jan, 2014 67 pages
Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion ...

Jan, 2014 68 pages
Pediarix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Pediarix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people ...

Jan, 2014 65 pages
Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is ... well as a SWOT analysis. Sales forecast for Infanrix Hexa for top six countries from 2012 to 2022. Sales information covered for the US, ...

Jan, 2014 65 pages
Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are ...

Jan, 2014 66 pages
Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people ...

Jan, 2014 91 pages
Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people ...

Jan, 2014 64 pages
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - US Drug Forecast and Market Analysis to 2022 US$ 4,995.00

Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV- ...

Jan, 2014 136 pages
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that ... analysis. Sales forecast for the top drugs in Japan from 2012-2022. Analysis of the impact of key events as well the drivers ...

Jan, 2014 89 pages
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Canada Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that ... analysis. Sales forecast for the top drugs in Canada from 2012-2022. Analysis of the impact of key events as well the drivers ...

Jan, 2014 129 pages
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022 US$ 6,995.00

Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV- ...

Jan, 2014 191 pages
Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

... B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that ... analysis. Sales forecast for Engerix-B for top seven countries from 2012 to 2022. Sales information covered for the US, Canada, France, ...

Jan, 2014 67 pages
Comvax (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

... B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that ... analysis. Sales forecast for Comvax for the US from 2012 to 2022. Sales information covered for the US Reasons to buy Understand and ...

Jan, 2014 64 pages
Bimmugen (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

... B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that ... and chronic infections caused by all known strains of HBV. In 1988, Bimmugen became the first HBV vaccine available in Japan. The antigen ...

Jan, 2014 61 pages
Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV- ...

Jan, 2014 64 pages
Global Therapeutic Vaccines Market 2014-2018 US$ 2,500.00

... market. TechNavio's report, the Global Therapeutic Vaccines Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry ... The report also includes a discussion of the key vendors operating in this market. Key Regions Americas EMEA APAC Key Vendors Agenus Inc. ...

Mar, 2014 54 pages
Market Research Report on Global and Chinese Vaccine linkage production line Industry, 2009-2019 US$ 2,400.00

... linkage production line Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Vaccine linkage production line industry. The ... of each company; The breakdown data of Vaccine linkage production line market are presented by company, by country, and by application; The report also ...

Mar, 2014 150 pages
Market Research Report on Global and Chinese Influenza Vaccine Industry, 2009-2019 US$ 2,400.00

... Chinese Influenza Vaccine Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Influenza Vaccine industry. The report ... economic parameters of each company; The breakdown data of Influenza Vaccine market are presented by company, by country, and by application; The report also ...

Feb, 2014 150 pages
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022 US$ 9,995.00

... , in particular pediatric combination vaccines and novel adult vaccines, are anticipated to dramatically influence market growth. Scope Overview of hepatitis B virus (HBV), including etiology, general symptoms from infection, and country-specific immunization recommendations and vaccination coverage data. ...

Jan, 2014 303 pages
Vaccine Deals and Alliances of 2013 US$ 1,495.00

The Vaccine Deals and Alliances of 2013 provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2013. Using these reports, dealmakers will effectively and efficiently gain insight into the ...

Mar, 2014 200 pages
HIV Vaccine Market Opportunity & Clinical Pipeline Analysis US$ 2,000.00

... . It has been observed that almost nine out of every ten HIV infections are being diagnosed in the developing countries, and two- ... have a high probability of succeeding, instead of those which are less promising. “HIV Vaccine Market Opportunity & Clinical Pipeline Analysis” Report Highlights: Introduction ...

Mar, 2014 330 pages
Global Human Vaccine Industry 2013-2018: Trend, Profit, and Forecast Analysis, April 2013 US$ 2,499.00

... are the other players in the top five players list. Lucintel, a leading global management consulting and market research firm, has conducted a competitive analysis of the industry and presents its findings in Global Human Vaccine Industry 2013-2018: Trend, Profit, and Forecast Analysis. North ...

Apr, 2013 168 pages
PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update US$ 9,995.00

PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update Summary Seasonal Influenza is a respiratory infection ... to gain a competitive advantage. Track drug sales in the global seasonal influenza vaccine market from 2012-2022. Organize your sales and ...

Sep, 2013 332 pages
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update US$ 9,995.00

PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update Summary Meningococcal disease is an acute infection caused ... for each age segment and country? Which meningococcal vaccines will face adoption challenges in the market? What is the projected uptake ...

Aug, 2013 316 pages
US Cancer Vaccine Market Outlook 2018 US$ 1,200.00

... depending on the location are applied when purchasing CD ROM or Hard Copy License. Cancer vaccines are a viable option for treating many types ... to a combined share of 50% accounted for by Europe and other regions. “US Cancer Vaccine Market Outlook 2018” research study by KuicK Research gives comprehensive ...

Feb, 2014 142 pages
Global Vaccine Market Pipeline Analysis US$ 1,500.00

... sub-divided into four groups namely, pediatrics, adolescents, adults and elderly. Though the vaccines segment forms a very small portion of the ... market is expected to surpass estimated USD 100 billion by 2025. “Global Vaccine Market Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ...

Jan, 2014 1150 pages
2014 Deep Research Report on China Influenza Vaccine Industry US$ 2,200.00

Summary '2014 Deep Research Report on China Influenza Vaccine Industry' was a professional and depth research report on China Influenza Vaccine Industry. Firstly the report describes the background knowledge of Influenza Vaccine, including Concepts Classification Manufacturing process ...

Jan, 2014 201 pages
US Cancer Vaccine Pipeline Analysis US$ 1,500.00

... for entry. Constituting almost 50% of the global pie, the US cancer vaccine market was estimated to be worth USD 14 Billion in 2012. With close ... cancer every year, this market is expected to o reach USD 20 billion by 2020. “US Cancer Vaccine Pipeline Analysis” by PNS Pharma gives comprehensive insight on the ...

Jan, 2014 300 pages
Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis US$ 1,990.00

... 1. Influenza 2. Cervical Cancer/ HPV 3. Hepatitis 4. Zoster Shingles 5. Pneumococcal 6. Measles, Mumps, Rubella and Varicella (MMRV) 7. Meningococcal 8. Diphtheria, Tetanus, Pertussis (DTP) 9. Travel and Miscellaneous Companies’ Adult Vaccines Sales Share and Forecast data (2007 – 2020) covered in the ...

Nov, 2013 222 pages
Research Report on China Swine Fever Vaccine Industry, 2013-2017 US$ 1,300.00

... acute, hyperpyretic and contagious disease, caused by swine fever viruses. Its incidence rate and death rate are both extremely high, and viruses ... industry Supply and demand status of China swine fever vaccines Factors influencing the development of swine fever vaccine market Government procurement system ...

Oct, 2013 30 pages
Research Report on China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry, 2013-2017 US$ 1,300.00

... PRRS is the most serious disease that impairs the pig raising & breeding industry. It inflicted heavy losses on China pig raising & breeding industry ... syndrome in China China pig raising & breeding industry status Supply and demand status of China porcine reproductive and respiratory syndrome (PRRS) vaccines ...

Oct, 2013 30 pages
Research Report on China Avian Influenza Vaccine Industry, 2013-2017 US$ 1,300.00

... than 10 years ago, some poultry raising farms in China used the H5N1 avian influenza vaccine. They were not forced but voluntary to ... . To resolve these problems, Ministry of Agriculture of China set up an entry barrier of the avian influenza vaccine producing market and tightly supervised it. It established ...

Oct, 2013 30 pages
Research Report on China Foot and Mouth Disease (FMD) Vaccine Industry, 2013-2017 US$ 1,200.00

... Bio-Technology Co., Ltd. accounting for 80%. Because there are a few FMD vaccine manufacturers in China with high market concentration rate, government's purchasing ... vaccine industry. Through this report, the readers can acquire the following information: Incidence status of Foot and Mouth Disease in China ...

Oct, 2013 30 pages
Global DNA Vaccine Pipeline Analysis US$ 1,500.00

... West Nile Virus to be used in horses was approved in 2005. 'Global DNA Vaccine Pipeline Analysis' by PNS Pharma gives comprehensive insight on the various ... holders to identify and analyze the available investment opportunity in the DNA vaccine market based upon development process. Following parameters for ...

Oct, 2013 130 pages
Research Report on China's Haemophilus Influenza B (HIB) Vaccine Industry, 2013-2017 US$ 1,200.00

... influenza type B is a kind of haemophilus influenza with extremely strong invasiveness. Among all the serious infections caused by haemophilus influenzas, almost 90% were caused by haemophilus influenza type B. According to the researches in recent years, HIB has become the first bacteria that will cause ...

Aug, 2013 20 pages
Research Report on China Human Rabies Vaccine Industry, 2013-2017 US$ 1,200.00

... , but the rabies vaccination rate of dogs is less than 10%. Second, China lacks a coordination and management mechanism among departments involving in rabies ... the following information or even more: Development environment of China human rabies vaccines China rabies status overview Supply and demand status ...

Sep, 2013 20 pages
Research Report on China Measles, Mumps and Rubella (MMR) Vaccine Market, 2013-2017 US$ 1,200.00

... (incidence rate: below 1/100,000,000). In 2012, China's lot released volume of measles vaccines reached 8.651 million person-servings, decreasing ... vaccines manufactured by Merck violated the approval process of imported vaccines in China because it lacked alerts in the specification and existed safety risks. ...

Sep, 2013 20 pages
Global Vaccine Market to 2017 - Market Size, Growth, and Forecasts in Over 70 Countries US$ 2,570.00

Global Vaccine Market to 2017 - Market Size, Growth and Forecasts in Over 70 Countries is a comprehensive publication that enables readers the critical perspectives ... and trends for the following kinds of products: Human vaccines Veterinary vaccines The publication is designed for companies who want to gain ...

Jun, 2013
Vaccine Market - By Technology & Types, Trend Analysis By Various Classes - Live / Attenuated, Subunit, Toxoid, Conjugate, DNA, Recombinant Vector, Synthetic, Dentritic Vaccines And By... US$ 4,650.00

... have also been discussed. A large number of potential therapeutic and preventive vaccine candidates addressing various diseases which are in the pipeline are ... 2012 and 2013, as well as the forecast up to 2022. Global Vaccine Market, by Technology Class Live Toxoid Conjugate Sub-Unit Recombinant Vector ...

Aug, 2013 195 pages
2013 Deep Research Report on China Varicella Vaccine Industry US$ 15,000.00

2013 Deep Research Report on China Varicella Vaccine Industry was professional and depth research report on China Varicella Vaccine industry. This ... manufacturing technology and product specifications, And then summary statistics China major Varicella Vaccine manufacturers 2010-2016 Varicella Vaccine capacity ...

Mar, 2013 47 pages
2013 Deep Research Report on China Japanese Encephalitis Vaccine Industry US$ 1,400.00

2013 Deep Research Report on China Japanese Encephalitis Vaccine Industry was professional and depth research report on China Japanese Encephalitis Vaccine ... price cost gross margin and production value, and also introduced China 5 manufacturers company basic information, 2010-2016 Japanese Encephalitis Vaccine ...

Mar, 2013 63 pages
2013 Deep Research Report on China Hepatitis B Vaccine Industry US$ 2,000.00

2013 Deep Research Report on China Hepatitis B Vaccine Industry was professional and depth research report on China Hepatitis B Vaccine industry. This report has firstly introduced Hepatitis B Vaccine definition classification industry chain etc related information. Then ...

Jan, 2013 173 pages
Research Report on Global and China Human Vaccine Industry, 2013-2017 US$ 2,200.00

... Type B Haemophilus Influenzae Conjugate Vaccine, Influenza Vaccine, Rabies Vaccine and so on. In China, Vaccine I market are occupied by state-owned enterprises, while foreign- ... market will rise continually. Due to the low vaccination rate in China, there's much space for future growth. With the increase of ...

Aug, 2013 50 pages
Hepatitis Drugs and Vaccines: World Market 2013-2023 US$ 2,635.00

... . What prospects for regions and countries? Developments worldwide expand the hepatitis products market, especially rising demand for medicines in emerging countries. ... you possibilities, helping you stay ahead. Nine ways Hepatitis Drugs and Vaccines: World Market 2013-2023 helps you To sum up, our ...

Jun, 2013 197 pages
China Poultry Vaccine Market Analysis US$ 3,980.00

... industry, price trends, import and export data, projects to be constructed in China, forecasts, as well as technologies and investment status, risks and trends ... against any of the companies in this field, then China poultry vaccine market analysis is required reading. This report can be delivered immediately ...

Jul, 2013 92 pages
Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report US$ 2,649.00

... Biosciences presents a comprehensive industry analysis of the cancer vaccines space as well as that of the emerging circulating tumor cells (CTCs) space. These two ... This report also examines the technology and market landscape for circulating tumor cells (CTCs). There is currently much interest in CTCs as they ...

Jan, 2011 139 pages
PharmaPoint: Meningococcal Vaccines - UK Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... Market Analysis to 2022 Summary GlobalData has released its new Country report, 'PharmaPoint: Meningococcal Vaccines - UK Drug Forecast and Market Analysis to 2022'. ... predicts that relative patient share for the three MenC conjugate vaccines will shift due to changes being made to the UK MenC schedule ( ...

Sep, 2013 102 pages
PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... Market Analysis to 2022 Summary GlobalData has released its new Country report, 'PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022'. ... Pfizer will target adolescents with its MenB vaccine, an approach that should facilitate rapid uptake, given the ACIP’s current immunization ...

Sep, 2013 95 pages
1 2 3 4 5 >
Skip to top